Abstract 4783
Background
Many studies have suggested that dietary calcium has a protective effect on colon cancer development. The mean dietary calcium intake of Koreans is 490 mg/day, which is far less than the recommended intake of calcium 700-800mg/day. In this study, we explored the relationship between dietary calcium intake and colorectal cancer development in Koreans with relatively low calcium intake compared to Western countries.
Methods
The Health Examinees (HEXA) Study, large-scale genomic community-based prospective cohort study was designed to identify the general characteristics of major chronic disease in Korean. Participants in this analysis consisted with 135,230 participants aged 40-69 years recruited between 2004 and 2013. The calcium intake level was categories by Dietary Reference Intakes for Koreans (KDRIs). Cox proportional hazards regression model was used to estimate hazard ratio (HR) and corresponding 95% confidence intervals (CI) for colorectal cancer risk adjusting for potential confounders.
Results
Median energy-adjusted calcium intake was 385.5mg/day in men and 420.2mg/day in women. In the multivariate-adjusted model, compared with the group consumed less than the recommended intake of calcium, the group consumed more than the recommended intake of calcium showed a marginally significant reduction in the risk of colorectal cancer in women. (HR = 0.62, 95% CI: 0.38-1.02). But, among men, no significant association were observed between the dietary calcium intake and colorectal cancer risk (HR = 0.88, 95% CI: 0.56-1.37).
Conclusions
Korean women who adhere to the recommended intake of calcium showed a reduced risk of colorectal cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Research Foundation of Korea, No. 2017R1A2B4009233.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3907 - Exploration of efficacious alternative regorafenib regimens to manage hand-foot-skin-reaction (HFSR)
Presenter: Axel Grothey
Session: Poster Display session 2
Resources:
Abstract
3958 - Quality of Life (QoL) in Metastatic Colorectal Cancer (mCRC) in the Real World: Final Results of a European Survey
Presenter: Zorana Maravic
Session: Poster Display session 2
Resources:
Abstract
3563 - BISQUIT: A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal
Presenter: Rachel Riechelmann
Session: Poster Display session 2
Resources:
Abstract
1184 - iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer
Presenter: Fiona Turkes
Session: Poster Display session 2
Resources:
Abstract
3346 - Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA Study
Presenter: Lisa Salvatore
Session: Poster Display session 2
Resources:
Abstract
3895 - A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study.
Presenter: Maria Aurelia Barbera
Session: Poster Display session 2
Resources:
Abstract
2012 - Open Label Phase III Study of Arfolitixorin vs. Leucovorin in mFOLFOX-6 for First Line Treatment of Metastatic Colorectal Cancer: AGENT
Presenter: Josep Tabernero
Session: Poster Display session 2
Resources:
Abstract
2198 - SOLSTICE, a phase 3, randomized, open label study of trifluridine/tipiracil+bevacizumab (bev) versus capecitabine+bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy
Presenter: Thierry Andre
Session: Poster Display session 2
Resources:
Abstract
2921 - A Phase Ib/ II Trial to Assess the Safety and Efficacy of CXD101 in Combination with the PD-1 Inhibitor Nivolumab in Patients with Metastatic, Previously-Treated, Microsatellite-Stable (MSS) Colorectal Carcinoma (short title CAROSELL)
Presenter: Mark Saunders
Session: Poster Display session 2
Resources:
Abstract
3695 - A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination with FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS Mutation
Presenter: Heinz Josef Lenz
Session: Poster Display session 2
Resources:
Abstract